BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Last trade$76.64
Day change-$0.72 (-0.93%)
Day range$74.89 – $77.72
Volume2,047,491
Market cap$15.07B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.07B
Price / earnings
—
Price / book
-9.07×
Price / sales
15.94×
EV / sales
16.94×
EV / EBITDA
-45.97×
Profitability
Earnings per share
-$3.04
Return on assets
-27.39%
Return on equity
35.62%
Dividend yield
0.02%
Liquidity and leverage
Debt / equity
-1.49×
Current ratio
2.09×
Quick ratio
2.03×
Cash ratio
1.57×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$369.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$353.17M
$243.68M
$194.52M
$154.18M
$120.7M
$110.57M
$116.63M
$5.88M
Cost of revenue
$20.45M
$15.05M
$9.94M
$8.11M
$6.56M
$3.65M
$2.64M
$2.08M
Gross profit
$332.72M
$228.63M
$184.58M
$146.07M
$114.14M
$106.91M
$113.99M
$3.8M
Selling, general and administrative
$200.85M
$186.26M
$163.9M
$158.09M
$137.62M
$129.15M
$106.37M
$94.78M
Research and development
$143.51M
$149.45M
$126.64M
$116.42M
$112.87M
$111.23M
$111.43M
$130.35M
Total operating expenses
$344.36M
$335.71M
$290.53M
$285.63M
$259.34M
$241.19M
$218.37M
$229.83M
Operating income
-$11.64M
-$107.08M
-$105.96M
-$139.56M
-$145.2M
-$134.28M
-$104.37M
-$226.03M
Interest expense
-$13.26M
-$13.28M
-$12.94M
-$11.64M
-$11.74M
-$11.61M
-$18.12M
-$21.52M
Income before taxes
-$59.27M
-$155.89M
-$166.56M
-$194.76M
-$186.48M
-$181.66M
-$169.61M
-$266.24M
Income taxes
$1.23M
$0
$0
-$120K
-$1.55M
$2.1M
$0
$1.15M
Net income
-$60.5M
-$155.89M
-$166.56M
-$194.64M
-$184.94M
-$183.76M
-$169.61M
-$267.39M
Net income attributable to common shareholders
-$83M
-$152.22M
-$164.04M
-$192.86M
-$182.74M
-$181.9M
-$167.42M
-$265.05M
EBITDA
-$10.57M
-$106.03M
-$104.77M
-$127M
-$134.96M
-$132.16M
-$102.52M
-$219.97M
Basic earnings per share
-$0.42
-$0.78
-$0.84
-$1.00
-$0.95
-$0.95
-$0.88
-$1.40
Diluted earnings per share
-$0.42
-$0.78
-$0.84
-$1.00
-$0.95
-$0.95
-$0.88
-$1.40
Recent news
Company coverage with links to the original publishers.
BridgeBio Pharma is positioned for a potential breakout with three therapies approaching FDA approval over the next seven months. The company demonstrated strong commercial execution with Q3 2026 revenues up 193% year-over-year, driven primarily by its heart disease drug Attruby. With over $1.5 billion in cash and established sales teams ready for new product launches, BridgeBio appears well-positioned for growth, though risks remain inherent to small biotech companies focused on rare diseases.
Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.
An independent real-world study of 2,684 ATTR-CM patients from U.S. electronic health records found that acoramidis was associated with an 18% lower risk of death, hospitalization, atrial fibrillation, and diuretic intensification compared to tafamidis. Acoramidis showed 27% lower risk of cardiovascular and heart failure hospitalizations. These findings replicate earlier comparative effectiveness analyses and support acoramidis as a preferred stabilizer treatment option.
BridgeBio announced positive Phase 3 CALIBRATE trial results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), showing 91% of participants achieved normal PTH levels compared to 0% on standard care, with 100% reporting symptom improvements versus 46% on conventional therapy. The FDA accepted the NDA with Priority Review (PDUFA date May 8, 2027), and the company initiated the Phase 3 RECLAIM-HP trial for chronic hypoparathyroidism.
BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.